Literature DB >> 22342309

Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis.

Chen Huang1, Keping Xie.   

Abstract

Pancreatic cancer progression is attributed to genetic and epigenetic alterations and a chaotic tumor microenvironment. Those diverse "upstream signal" factors appear to converge on specific sets of central nuclear regulators, namely, transcription factors. Specificity Protein 1 (Sp1) and signal transducer and activator of transcription 3 (Stat3) are central transcription factors that regulate a number of pathways important to tumorigenesis, including tumor cell-cycle progression, apoptosis, angiogenesis, metastasis, and evasion of the immune system. Recently, researchers demonstrated many types of crosstalk of Sp1 and Stat3 in tumor signal transduction and that these factors function cooperatively to activate targeted genes and promote tumorigenesis in pancreatic cancer. Therefore, targeting both Sp1 and Stat3 is a potential preventive and therapeutic strategy for pancreatic cancer. Copyright Â
© 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22342309      PMCID: PMC3307878          DOI: 10.1016/j.cytogfr.2012.01.003

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  140 in total

Review 1.  The Sp-family of transcription factors.

Authors:  G Suske
Journal:  Gene       Date:  1999-10-01       Impact factor: 3.688

2.  RNA interference is mediated by 21- and 22-nucleotide RNAs.

Authors:  S M Elbashir; W Lendeckel; T Tuschl
Journal:  Genes Dev       Date:  2001-01-15       Impact factor: 11.361

Review 3.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

4.  Stat5 and Sp1 regulate transcription of the cyclin D2 gene in response to IL-2.

Authors:  A Martino; J H Holmes; J D Lord; J J Moon; B H Nelson
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

Review 5.  Progression model for pancreatic cancer.

Authors:  R H Hruban; M Goggins; J Parsons; S E Kern
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

6.  Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma.

Authors:  A Zannetti; S Del Vecchio; M V Carriero; R Fonti; P Franco; G Botti; G D'Aiuto; M P Stoppelli; M Salvatore
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

Review 7.  STATs in oncogenesis.

Authors:  T Bowman; R Garcia; J Turkson; R Jove
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

Review 8.  STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription.

Authors:  R Catlett-Falcone; W S Dalton; R Jove
Journal:  Curr Opin Oncol       Date:  1999-11       Impact factor: 3.645

9.  Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling.

Authors:  D Sinibaldi; W Wharton; J Turkson; T Bowman; W J Pledger; R Jove
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

10.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.

Authors:  P K Epling-Burnette; J H Liu; R Catlett-Falcone; J Turkson; M Oshiro; R Kothapalli; Y Li; J M Wang; H F Yang-Yen; J Karras; R Jove; T P Loughran
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

View more
  26 in total

1.  FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.

Authors:  Chen Huang; Dacheng Xie; Jiujie Cui; Qi Li; Yong Gao; Keping Xie
Journal:  Clin Cancer Res       Date:  2014-01-22       Impact factor: 12.531

2.  MicroRNA-429 inhibits gastric cancer migration and invasion through the downregulation of specificity protein 1.

Authors:  Jingbin Ni; Yisha Yang; Di Liu; Hui Sun; Shimao Jin; Jingying Li
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

3.  FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis.

Authors:  Chen Huang; Jiawei Du; Keping Xie
Journal:  Biochim Biophys Acta       Date:  2014-01-11

Review 4.  Anti-Cancer Effects of Dietary Polyphenols via ROS-Mediated Pathway with Their Modulation of MicroRNAs.

Authors:  Yasukiyo Yoshioka; Tomokazu Ohishi; Yoriyuki Nakamura; Ryuuta Fukutomi; Noriyuki Miyoshi
Journal:  Molecules       Date:  2022-06-14       Impact factor: 4.927

5.  Tumor-suppressing effects of microRNA-429 in human renal cell carcinoma via the downregulation of Sp1.

Authors:  Deyao Wu; Xiaobing Niu; Huixing Pan; Yunfeng Zhou; Zichun Zhang; Ping Qu; Jian Zhou
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

6.  Detection of four polymorphisms in 5' upstream region of PNPLA2 gene and their associations with economic traits in pigs.

Authors:  Lihe Dai; Xiaohong Chu; Fuzeng Lu; Ruhai Xu
Journal:  Mol Biol Rep       Date:  2016-08-26       Impact factor: 2.316

Review 7.  Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications.

Authors:  Xiangyu Kong; Lei Li; Zhaoshen Li; Keping Xie
Journal:  Cytokine Growth Factor Rev       Date:  2012-07-01       Impact factor: 7.638

8.  Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.

Authors:  Xiangyu Kong; Lei Li; Zhaoshen Li; Xiangdong Le; Chen Huang; Zhiliang Jia; Jiujie Cui; Suyun Huang; Liwei Wang; Keping Xie
Journal:  Cancer Res       Date:  2013-04-18       Impact factor: 12.701

9.  RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch.

Authors:  L A Walsh; D M Roy; M Reyngold; D Giri; A Snyder; S Turcan; C R Badwe; J Lyman; J Bromberg; T A King; T A Chan
Journal:  Oncogene       Date:  2014-06-16       Impact factor: 9.867

10.  Molecular markers associated with outcome and metastasis in human pancreatic cancer.

Authors:  Anke Van den Broeck; Hugo Vankelecom; Rudy Van Eijsden; Olivier Govaere; Baki Topal
Journal:  J Exp Clin Cancer Res       Date:  2012-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.